ABSTRACT
Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) present a global clinical threat, as these ß-lactamases confer resistance to carbapenems and oxyimino-cephalosporins. Recent clinically identified KPC variants with substitutions at Ambler position D179, located in the Ω loop, are resistant to the ß-lactam/ß-lactamase inhibitor combination ceftazidime-avibactam, but susceptible to meropenem-vaborbactam. To gain insights into ceftazidime-avibactam resistance conferred by D179N/Y variants of KPC-2, crystal structures of these variants were determined. The D179N KPC-2 structure revealed that the change of the carboxyl to an amide moiety at position 179 disrupted the salt bridge with R164 present in wild-type KPC-2. Additional interactions were disrupted in the Ω loop, causing a decrease in the melting temperature. Shifts originating from N179 were also transmitted toward the active site, including â¼1-Å shifts of the deacylation water and interacting residue N170. The structure of the D179Y KPC-2 ß-lactamase revealed more drastic changes, as this variant exhibited disorder of the Ω loop, with other flanking regions also being disordered. We postulate that the KPC-2 variants can accommodate ceftazidime because the Ω loop is displaced in D179Y or can be more readily displaced in D179N KPC-2. To understand why the ß-lactamase inhibitor vaborbactam is less affected by the D179 variants than avibactam, we determined the crystal structure of D179N KPC-2 in complex with vaborbactam, which revealed wild-type KPC-2-like vaborbactam-active site interactions. Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Ω loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility.
Subject(s)
Ceftazidime , beta-Lactamase Inhibitors , Anti-Bacterial Agents/pharmacology , Azabicyclo Compounds/pharmacology , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Ceftazidime/pharmacology , Drug Combinations , Klebsiella pneumoniae/genetics , Meropenem/pharmacology , Microbial Sensitivity Tests , beta-Lactamase Inhibitors/pharmacology , beta-Lactamases/geneticsABSTRACT
Detection of 1,3-ß-d-glucan (BDG) in serum has been evaluated for its inclusion as a mycological criterion of invasive fungal infections (IFI) according to EORTC and Mycoses Study Group (MSG) definitions. BDG testing may be useful for the diagnosis of both invasive aspergillosis and invasive candidiasis, when interpreted in conjunction with other clinical/radiological signs and microbiological markers of IFI. However, its performance and utility vary according to patient population (hematologic cancer patients, solid-organ transplant recipients, intensive care unit patients) and pretest likelihood of IFI. The objectives of this article are to provide a systematic review of the performance of BDG testing and to assess recommendations for its use and interpretation in different clinical settings.
Subject(s)
Candidiasis, Invasive , Invasive Fungal Infections , beta-Glucans , Adult , Candidiasis, Invasive/diagnosis , Glucans , Humans , Invasive Fungal Infections/diagnosis , Sensitivity and SpecificityABSTRACT
The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, mean (± SD) plasma PK parameters of isavuconazole were: C max 4.00±1.45 mg/L, C min 1.76±0.76 mg/L, t ½ 48.36±29.78 h, Vss 288.78±182.11 L, CLss 4.85±3.79 L/h, and AUC 54.01±20.98 mg â h/L. Transmembrane clearance represented just 0.7% of the total isavuconazole clearance. These data suggest that isavuconazole is not readily removed by CRRT and no dose adjustments are necessary.
ABSTRACT
OBJECTIVES: To ensure the accuracy of susceptibility testing methods for ceftazidime/avibactam. METHODS: The performances of the Etest (bioMérieux), 30/20 µg disc (Hardy diagnostics) and 10/4 µg disc (Mast Group) were evaluated against the reference broth microdilution (BMD) method for 102 clinically relevant Gram-negative organisms: 69 ceftazidime- and meropenem-resistant Klebsiella pneumoniae and 33 MDR non-K. pneumoniae. Essential and categorical agreement along with major and very major error rates were determined according to CLSI guidelines. RESULTS: A total of 78% of isolates were susceptible to ceftazidime/avibactam. None of the three methods met the defined equivalency threshold against all 102 organisms. The Etest performed the best, with categorical agreement of 95% and major errors of 6.3%. Against the 69 ceftazidime- and meropenem-resistant K. pneumoniae, only the Etest and the 10/4 µg disc met the equivalency threshold. None of the three methods met equivalency for the 33 MDR isolates. There were no very major errors observed in any analysis. These results were pooled with those from a previous study of 74 carbapenem-resistant Enterobacteriaceae and data from the ceftazidime/avibactam new drug application to define optimal 30/20 µg disc thresholds using the error-rate bound model-based approaches of the diffusion breakpoint estimation testing software. This analysis identified a susceptibility threshold of ≤19 mm as optimal. CONCLUSIONS: Our data indicate that the Etest is a suitable alternative to BMD for testing ceftazidime/avibactam against ceftazidime- and meropenem-resistant K. pneumoniae. The 30/20 µg discs overestimate resistance and may lead to the use of treatment regimens that are more toxic and less effective.
Subject(s)
Anti-Bacterial Agents/pharmacology , Azabicyclo Compounds/pharmacology , Ceftazidime/pharmacology , Gram-Negative Bacteria/drug effects , Microbial Sensitivity Tests/methods , beta-Lactamase Inhibitors/pharmacology , Drug Combinations , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacterial Infections/microbiology , Humans , beta-Lactam ResistanceABSTRACT
INTRODUCTION: The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear. CASE REPORT: We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation. CONCLUSIONS: Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation.
Subject(s)
Abatacept/adverse effects , Immunosuppressive Agents/adverse effects , Invasive Pulmonary Aspergillosis/chemically induced , Lung Transplantation , Salvage Therapy/adverse effects , Female , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Invasive Pulmonary Aspergillosis/pathology , Middle Aged , Salvage Therapy/methods , Trachea/microbiologyABSTRACT
Bacterial pneumonia and tracheobronchitis are diagnosed frequently following lung transplantation. The diseases share clinical signs of inflammation and are often difficult to differentiate based on culture results. Microbiome and host immune-response signatures that distinguish between pneumonia and tracheobronchitis are undefined. Using a retrospective study design, we selected 49 bronchoalveolar lavage fluid samples from 16 lung transplant recipients associated with pneumonia (n = 8), tracheobronchitis (n = 12) or colonization without respiratory infection (n = 29). We ensured an even distribution of Pseudomonas aeruginosa or Staphylococcus aureus culture-positive samples across the groups. Bayesian regression analysis identified non-culture-based signatures comprising 16S ribosomal RNA microbiome profiles, cytokine levels and clinical variables that characterized the three diagnoses. Relative to samples associated with colonization, those from pneumonia had significantly lower microbial diversity, decreased levels of several bacterial genera and prominent multifunctional cytokine responses. In contrast, tracheobronchitis was characterized by high microbial diversity and multifunctional cytokine responses that differed from those of pneumonia-colonization comparisons. The dissimilar microbiomes and cytokine responses underlying bacterial pneumonia and tracheobronchitis following lung transplantation suggest that the diseases result from different pathogenic processes. Microbiomes and cytokine responses had complementary features, suggesting that they are closely interconnected in the pathogenesis of both diseases.
Subject(s)
Bronchitis/diagnosis , Bronchoalveolar Lavage Fluid/microbiology , Cytokines/metabolism , Lung Transplantation/adverse effects , Microbiota , Pneumonia, Bacterial/diagnosis , Tracheitis/diagnosis , Adult , Aged , Bayes Theorem , Bronchitis/etiology , Bronchitis/metabolism , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Pneumonia, Bacterial/etiology , Pneumonia, Bacterial/metabolism , Retrospective Studies , Tracheitis/etiology , Tracheitis/metabolism , Transplant RecipientsABSTRACT
Guidelines recommend targeted antifungal prophylaxis for liver transplant (LT) recipients based on tiers of risk, rather than universal prophylaxis. The feasibility and efficacy of tiered, targeted prophylaxis is not well established. We performed a retrospective study of LT recipients who received targeted prophylaxis (n = 145; voriconazole [VORI; 54%], fluconazole [8%], no antifungal [38%]) versus universal VORI prophylaxis (n = 237). Median durations of targeted and universal prophylaxis were 11 and 6 days, respectively (p < 0.0001). The incidence of invasive fungal infections (IFIs) in targeted and universal groups was 6.9% and 4.2% (p = 0.34). Overall, intra-abdominal candidiasis (73%) was the most common IFI. Posttransplant bile leaks (p = 0.001) and living donor transplants (p = 0.04) were independent risk factors for IFI. IFIs occurred in 6% of high-risk transplants who received prophylaxis and 4% of low-risk transplants who did not receive prophylaxis (p = 1.0). Mortality rates (100 days) were 10% (targeted) and 7% (universal) (p = 0.26); attributable mortality due to IFI was 10%. Compliance with prophylaxis recommendations was 97%. Prophylaxis was discontinued for toxicity in 2% of patients. Targeted antifungal prophylaxis in LT recipients was feasible and safe, effectively prevented IFIs and reduced the number of patients exposed to antifungals. Bile leaks and living donor transplants should be considered high-risk indications for prophylaxis.
Subject(s)
Antifungal Agents/therapeutic use , Graft Rejection/epidemiology , Liver Diseases/complications , Liver Transplantation/adverse effects , Mycoses/prevention & control , Transplant Recipients , Adult , Aged , Algorithms , Female , Follow-Up Studies , Graft Rejection/microbiology , Graft Survival , Humans , Immunocompromised Host , Liver Diseases/microbiology , Liver Diseases/surgery , Male , Middle Aged , Mycoses/epidemiology , Mycoses/microbiology , Postoperative Complications , Prognosis , Retrospective Studies , Risk Factors , Tissue Donors , United States/epidemiologyABSTRACT
BACKGROUND: Few studies of Scedosporium infections following solid organ transplantation have been performed in the era of induction immunosuppression and widespread antifungal prophylaxis. METHODS: We performed a single-center, retrospective study of transplant recipients from 2000 through 2010 who had a positive Scedosporium culture. RESULTS: Among 27 patients, 67% (n = 18) and 33% (n = 9) were infected with Scedosporium apiospermum and Scedosporium prolificans, respectively. A total of 67% received induction immunosuppression and 74% received prior antifungal therapy. Isolates were broadly resistant to antifungals. Of these patients, 59% (n = 16) were colonized by Scedosporium, and 41% (n = 11) had disease (scedosporiosis). No significant clinical differences were seen between species. Colonization occurred exclusively in the lungs of lung transplant recipients (LTR). Scedosporiosis followed lung transplantation in 55%, and other organ transplants (multivisceral [18%]; and heart, liver, small intestine [9% each]) in 45%. Scedosporiosis was preceded by colonization in 36%. Diseases included pneumonia (64%), mediastinitis (18%), and fungemia/disseminated infections (18%). The 6-month outcomes were death in 55%, progression in 18%, stability in 9%, and resolution in 18%. Patients who died had earlier onset scedosporiosis post transplant (median: 80.5 vs. 1388 days; P = 0.04), and were more likely to have mediastinitis or disseminated infections than pneumonia (100% vs. 29%; P = 0.06). The 3 patients who developed scedosporiosis >1 year post transplant survived. All patients who survived were treated with a voriconazole-containing regimen. CONCLUSIONS: LTR were most susceptible to Scedosporium colonization and scedosporiosis, particularly within the lungs. Death was common with scedosporiosis in the first year after all types of organ transplants, consistent with profound immunosuppression and antifungal resistance, but not encountered thereafter.
Subject(s)
Mycoses/etiology , Organ Transplantation/adverse effects , Scedosporium/isolation & purification , Adult , Antifungal Agents/pharmacology , Drug Resistance, Fungal , Female , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Male , Microbial Sensitivity Tests , Middle Aged , Mycoses/microbiology , Retrospective Studies , Scedosporium/drug effects , Voriconazole/therapeutic useABSTRACT
Our objective was to model the cost-effectiveness and economic value of routine peri-operative Staphylococcus aureus screening and decolonization of lung and heart-lung transplant recipients from hospital and third-party payer perspectives. We used clinical data from 596 lung and heart-lung transplant recipients to develop a model in TreeAge Pro 2009 (Williamsport, MA, USA). Sensitivity analyses varied S. aureus colonization rate (5-15 %), probability of infection if colonized (10-30 %), and decolonization efficacy (25-90 %). Data were collected from the Cardiothoracic Transplant Program at the University of Pittsburgh Medical Center. Consecutive lung and heart-lung transplant recipients from January 2006 to December 2010 were enrolled retrospectively. Baseline rates of S. aureus colonization, infection and decolonization efficacy were 9.6 %, 36.7 %, and 31.9 %, respectively. Screening and decolonization was economically dominant for all scenarios tested, providing more cost savings and health benefits than no screening. Savings per case averted (2012 $US) ranged from $73,567 to $133,157 (hospital perspective) and $10,748 to $16,723 (third party payer perspective), varying with the probability of colonization, infection, and decolonization efficacy. Using our clinical data, screening and decolonization led to cost savings per case averted of $240,602 (hospital perspective) and averted 6.7 S. aureus infections (4.3 MRSA and 2.4 MSSA); 89 patients needed to be screened to prevent one S. aureus infection. Our data support routine S. aureus screening and decolonization of lung and heart-lung transplant patients. The economic value of screening and decolonization was greater than in previous models of other surgical populations.
Subject(s)
Carrier State/diagnosis , Carrier State/drug therapy , Mass Screening/economics , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Staphylococcus aureus/isolation & purification , Transplant Recipients , Academic Medical Centers , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Cohort Studies , Computer Simulation , Cost-Benefit Analysis , Female , Heart Transplantation , Humans , Infant , Lung Transplantation , Male , Mass Screening/methods , Middle Aged , Pennsylvania , Retrospective Studies , Young AdultABSTRACT
We conducted a retrospective study of 17 transplant recipients with carbapenem-resistant Klebsiella pneumoniae bacteremia, and described epidemiology, clinical characteristics and strain genotypes. Eighty-eight percent (15/17) of patients were liver or intestinal transplant recipients. Outcomes were death due to septic shock (18%), cure (24%) and persistent (>7 days) or recurrent bacteremia (29% each). Thirty- and 90-day mortality was 18% and 47%, respectively. Patients who were cured received at least one active antimicrobial agent and underwent source control interventions. Forty-one percent (7/17) of patients had intra-abdominal infections; all except one developed persistent/recurrent bacteremia despite drainage. Two patients tolerated persistent bacteremia for >300 days. All patients except one were infected with sequence type 258 (ST258), K. pneumoniae carbapenemase (KPC)-2-producing strains harboring a mutant ompK35 porin gene; the exception was infected with an ST37, KPC-3-producing strain. Seventy-one percent (12/17) of patients were infected with ST258 ompK36 mutant strains. In two patients, persistent bacteremia was caused by two strains with different ompK36 genotypes. Three ompK36 mutations were associated with significantly higher carbapenem minimum inhibitory concentrations than wild-type ompK36. Pulse-field gel electrophoresis identified a single ST258 lineage; serial strains from individual patients were indistinguishable. In conclusion, KPC-K. pneumoniae bacteremia exhibited highly diverse clinical courses following transplantation, and was caused by clonal ST258 strains with different ompK36 genotypes.
Subject(s)
Bacteremia/epidemiology , Carbapenems/pharmacology , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/genetics , Organ Transplantation , beta-Lactam Resistance/genetics , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/microbiology , DNA, Bacterial/genetics , Female , Follow-Up Studies , Humans , Klebsiella Infections/microbiology , Klebsiella Infections/mortality , Klebsiella pneumoniae/isolation & purification , Male , Microbial Sensitivity Tests , Middle Aged , Polymerase Chain Reaction , Prognosis , Retrospective Studies , Risk Factors , Survival RateABSTRACT
We conducted a retrospective study of deep surgical site infections (SSIs) among consecutive patients who underwent lung transplantation (LTx) at a single center from 2006 through 2010. Thirty-one patients (5%) developed SSIs at median 25 days after LTx. Empyema was most common (42%), followed by surgical wound infections (29%), mediastinitis (16%), sternal osteomyelitis (6%), and pericarditis (6%). Pathogens included Gram-positive bacteria (41%), Gram-negative bacteria (41%), fungi (10%) and Mycobacterium abscessus, Mycoplasma hominis and Lactobacillus sp. (one each). Twenty-three percent of SSIs were due to pathogens colonizing recipients' native lungs at time of LTx, suggesting surgical seeding as a source. Patient-related independent risk factors for SSIs were diabetes and prior cardiothoracic surgery; procedure-related independent risk factors were LTx from a female donor, prolonged ischemic time and number of perioperative red blood cell transfusions. Mediastinitis and sternal infections were not observed among patients undergoing minimally invasive LTx. SSIs were associated with 35% mortality at 1 year post-LTx. Lengths of stay and mortality in-hospital and at 6 months and 1 year were significantly greater for patients with SSIs other than empyema. In conclusion, deep SSIs were uncommon, but important complications in LTx recipients because of their diverse microbiology and association with increased mortality.
Subject(s)
Graft Rejection/mortality , Gram-Negative Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/epidemiology , Lung Diseases/complications , Lung Transplantation/adverse effects , Postoperative Complications , Surgical Wound Infection/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Graft Rejection/etiology , Gram-Negative Bacteria/pathogenicity , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/mortality , Gram-Positive Bacteria/pathogenicity , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Humans , Lung Diseases/mortality , Lung Diseases/surgery , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Surgical Wound Infection/etiology , Surgical Wound Infection/mortality , Survival Rate , United States/epidemiology , Young AdultABSTRACT
An increasing number of patients older than 65 years are referred for and have access to organ transplantation, and an increasing number of older adults are donating organs. Although short-term outcomes are similar in older versus younger transplant recipients, older donor or recipient age is associated with inferior long-term outcomes. However, age is often a proxy for other factors that might predict poor outcomes more strongly and better identify patients at risk for adverse events. Approaches to transplantation in older adults vary across programs, but despite recent gains in access and the increased use of marginal organs, older patients remain less likely than other groups to receive a transplant, and those who do are highly selected. Moreover, few studies have addressed geriatric issues in transplant patient selection or management, or the implications on health span and disability when patients age to late life with a transplanted organ. This paper summarizes a recent trans-disciplinary workshop held by ASP, in collaboration with NHLBI, NIA, NIAID, NIDDK and AGS, to address issues related to kidney, liver, lung, or heart transplantation in older adults and to propose a research agenda in these areas.
Subject(s)
Organ Transplantation , Aged , Health Care Rationing , Humans , Immunosuppressive Agents/therapeutic use , Patient Selection , Social Justice , Tissue Donors , Treatment OutcomeABSTRACT
Organisms contained in probiotics are generally regarded as non-pathogenic and safe to administer. However, increasing reports of probiotic-associated infection raise concern over the safety of these products. We report a case of Lactobacillus empyema in a human immunodeficiency virus-infected lung transplant recipient receiving a probiotic containing Lactobacillus rhamnosus GG. We compare the epidemiology of Lactobacillus infections in heart and lung transplant recipients at our institution before and after the introduction of this probiotic, and discuss the potential mechanism for Lactobacillus within the probiotic to cause infections and disseminate.
Subject(s)
Empyema, Pleural/microbiology , Gram-Positive Bacterial Infections/microbiology , Heart Transplantation/adverse effects , Lacticaseibacillus rhamnosus/pathogenicity , Lung Transplantation/adverse effects , Probiotics/therapeutic use , Empyema, Pleural/epidemiology , Gram-Positive Bacterial Infections/epidemiology , Humans , Lacticaseibacillus rhamnosus/classification , Lacticaseibacillus rhamnosus/genetics , Lacticaseibacillus rhamnosus/isolation & purification , Male , Middle Aged , RNA, Ribosomal, 16S/genetics , Sequence Analysis, DNAABSTRACT
Purulent pericarditis due to Mycoplasma hominis is rare, and is usually associated with mediastinitis or pleuritis following cardiothoracic surgery. We report the first case to our knowledge of isolated purulent pericarditis caused by M. hominis in a lung transplant recipient and review previously reported cases of this disease.
Subject(s)
Lung Transplantation , Mycoplasma Infections/etiology , Mycoplasma hominis , Pericarditis/microbiology , Postoperative Complications/microbiology , Adult , Echocardiography , Female , Humans , Infant, Newborn , Male , Middle Aged , Mycoplasma Infections/diagnosis , Pericardial Effusion/microbiology , Pericarditis/diagnostic imaging , Postoperative Complications/diagnostic imaging , RadiographyABSTRACT
We have evaluated the Platelia Aspergillus enzyme immunoassay for detection of galactomannan in bronchoalveolar lavage (BAL) specimens in solid organ transplant patients with aspergillosis. The precision and reproducibility in serum or BAL to which galactomannan was added were similar. Sensitivity was 81.8% in patients with aspergillosis, and specificity was 95.8% in lung transplant patients who underwent BAL for surveillance for infection or rejection. Among transplant controls, positive results were more common in patients (i) who underwent diagnostic BAL performed for evaluation of symptoms or chest computed tomographic abnormalities, (ii) who had undergone lung transplantation, or (iii) who were colonized with Aspergillus. Galactomannan testing in BAL is useful for diagnosis of aspergillosis in transplant patients. The significance of positive results in patients without confirmed aspergillosis requires further evaluation.
Subject(s)
Antigens, Fungal/analysis , Aspergillosis/diagnosis , Aspergillus/isolation & purification , Bronchoalveolar Lavage Fluid/immunology , Immunoenzyme Techniques , Mannans/analysis , Aspergillus/immunology , Galactose/analogs & derivatives , Humans , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
Candida albicans is the most common fungal opportunistic pathogen of humans and causes mucocutaneous, bloodstream and deep organ infections. Screening for C. albicans genes that are preferentially expressed within infected hosts represents a strategy to identify novel virulence factors and define global expression patterns relevant to pathogenesis. Until recently, C. albicans has not been amenable to screening using existing technologies. This has begun to change with the development of new molecular genetic tools and the sequencing of the C. albicans genome. In this paper, we review studies using recently developed techniques to identify genes expressed by C. albicans during infections, as well as work from our laboratory using a human antibody-based strategy. Along with others, we have shown that selected in vivo expressed genes encode known and previously unrecognized candidal virulence factors. Future studies in this area will identify additional novel virulence factors, as well as advance our understanding of pathogenesis.
Subject(s)
Candida albicans/pathogenicity , Candidiasis/microbiology , Fungal Proteins/metabolism , Gene Expression Profiling/methods , Gene Expression Regulation, Fungal , Animals , Fungal Proteins/genetics , Humans , Mice , Rats , VirulenceABSTRACT
Despite new antifungal treatment strategies, invasive aspergillosis (IA) remains a principal cause of infectious mortality after bone marrow transplantation (BMT). We reviewed the medical records of 93 allogeneic and 149 autologous transplant recipients during a 20 month period, with attention to cases of proven or probable IA. No autologous transplant recipient developed IA, whereas IA was seen in 15.1% of allogeneic recipients (including two of five patients with a prior history of IA despite prophylaxis), for an overall incidence of 5.8%. The median time to occurrence was 92 days post transplant, with no de novo cases developing prior to engraftment. Survival 100 days from diagnosis was 29%. Risk factors for the development of IA included > or = 21 days of corticosteroid therapy of >or= 1mg/kg/day and post-transplant cytomegalovirus (CMV) infection. These two risk factors were statistically linked. Our data illustrate a shift toward a later occurrence of post-transplant IA, suggesting a need for close, prolonged surveillance in the outpatient environment. The contributory role of protracted corticosteroid use is also highlighted. These data have important implications in an era of alternate donor transplants and more intense immunosuppression. Established strategies implementing newer, less toxic antifungal agents as prophylaxis in high-risk patients are needed.
Subject(s)
Aspergillosis/epidemiology , Bone Marrow Transplantation/adverse effects , Adolescent , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Aspergillosis/complications , Aspergillosis/microbiology , Aspergillus/classification , Aspergillus/isolation & purification , Bone Marrow Transplantation/mortality , Child , Child, Preschool , Cytomegalovirus Infections/complications , Female , Florida/epidemiology , Hospitals, University , Humans , Immunosuppression Therapy/adverse effects , Infant , Male , Middle Aged , Opportunistic Infections/complications , Opportunistic Infections/epidemiology , Opportunistic Infections/microbiology , Retrospective Studies , Risk Factors , Survival Rate , Time Factors , Transplantation, Autologous/adverse effects , Transplantation, Autologous/mortality , Transplantation, Homologous/adverse effects , Transplantation, Homologous/mortalityABSTRACT
The aim of this study was to define the epidemiology and clinical manifestations of late recurrent candidemia. For this purpose, late recurrent candidemia was defined as an episode of candidemia occurring at least 1 month after the apparent complete resolution of an infectious episode caused by the same Candida sp. A total of five patients with recurrent candidemia were investigated. For all patients, isolates from the initial and recurrent episodes of candidemia were available for in vitro susceptibility testing and genetic characterization by DNA-based techniques. The results revealed the following salient features: prolonged duration between the initial and recurrent episodes (range, 1-8 months); recurrence of candidemia despite anti-fungal therapy; importance of retained intravascular catheters, neutropenia, and corticosteroids as factors predisposing to recurrence; high morbidity and mortality; no emergence of antifungal drug resistance between the initial and recurrent episodes; and relapse of infection due to the original infecting strain, rather than reinfection with a new strain. These findings raise several issues about the management and follow-up of patients with candidemia, which require assessment in future studies.
Subject(s)
Candida/genetics , Candidiasis/microbiology , Fungemia/microbiology , Aged , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida/classification , Candida/drug effects , Candida/isolation & purification , Candidiasis/drug therapy , Candidiasis/epidemiology , DNA, Fungal/analysis , Female , Fungemia/drug therapy , Fungemia/epidemiology , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Molecular Epidemiology , Polymerase Chain Reaction/methods , RecurrenceABSTRACT
Infection of subcutaneous tissue by black fungi (subcutaneous phaeohyphomycosis) has only been reported in six transplant patients, all of whom were solid organ recipients. These patients presented with indolent, localized infections at least 1 year after transplant, while on maintenance immunosuppressive regimens. They were cured by surgical resection, either alone or in conjunction with antifungal agents. We report a case of subcutaneous phaeohyphomycosis occurring in a bone marrow transplant recipient receiving high doses of immunosuppressive agents, in whom widespread subcutaneous infection due to Exophiala jeanselmei was not eradicated by repeated resections and therapy with amphotericin B and flucytosine. The infection was eventually cured after addition of itraconazole to the therapeutic regimen. Results of in vitro testing of the isolate for susceptibility to a combination of amphotericin B, flucytosine and itraconazole confirmed the potential role of combination antifungal therapy in the setting of refractory infection.
Subject(s)
Antifungal Agents/therapeutic use , Bone Marrow Transplantation , Dermatomycoses/microbiology , Fungi/drug effects , Amphotericin B/therapeutic use , Biopsy , Combined Modality Therapy , Dermatomycoses/pathology , Dermatomycoses/therapy , Drug Resistance, Microbial , Drug Therapy, Combination , Flucytosine/therapeutic use , Fungi/isolation & purification , Humans , Itraconazole/therapeutic use , Male , Middle Aged , Skin/microbiology , Skin/pathologyABSTRACT
Ninety-nine Candida bloodstream isolates underwent testing for susceptibility to amphotericin B by the E test, and the results were correlated with patients' responses to amphotericin B. The MICs for isolates that were associated with therapeutic failure were significantly higher than the MICs for those associated with therapeutic success. A MIC of >/=0.38 microgram/ml identified isolates likely to be associated with therapeutic failure.